Introduction
The measurement of biomarkers is essential to assess the role of environmental exposures in human disease. Although methods such as GIS (georeferencing) and questionnaires have become more accurate, individual exposure assessment based on biomarker measurements tends to be the gold standard providing a quantitative assessment, at least in some circumstances, for individual exposures. Identification of such molecular entities is now eased by the recent developments in omics technologies, which introduced a wealth of potentially exciting intermediate biomarkers. Biomarker validation is crucial and relies on the identification of the hazardous component and the investigation and assessment of the potential underlying biological/biochemical process. Once biomarkers are validated, they ought to be incorporated in the exposure assessment to complement traditional approaches (e.g., GIS and questionnaire data) as well as in the continuum between exposure and disease.
Progress toward the achievement of any of the above steps is facilitated by the additional development of appropriate study designs. For chronic diseases such as cancer, the scheme in Fig. 1 has been proposed by Vineis and Perera [1] , to take full advantage of the different study designs currently available. The application (and refinement) of that kind of approach together with the development of dedicated analytical strategies constitutes an important component of future research, which would provide new insight into exposure and disease pathophysiology, based on already existing samples available in biobanks.
Biomarkers of exposure, intermediate biomarkers
We illustrate below, based on four practical examples, how the use of biomarkers could help in addressing epidemiological issues of primary importance.
Waste management and contaminated land
The measurement of heavy metals (e.g., cadmium) and persistent organic pollutants [POPs; including polychlorinated biphenyl (PCB)] in body fluids is now very accurate and corresponds well to important criteria for exposure biomarkers. They can be integrated with the study of biomarkers of early effect (e.g., cadmium, which is involved in DNA repair impairment and PCBs, which impact on the immune system).
Air pollution and mixtures
The geographical variations in air composition are typically dominated by vehicle exhaust. The corresponding air pollutants encompass many different chemicals, including polycyclic aromatic hydrocarbon (PAH), benzene, 1,3-butadiene, as well as NOx and particles. However, in selected areas, exposure to pesticides or pollutants from point sources (factories) can also play a local but critical role. Biomarkers can either relate to the pool of chemical components and/or to a specific subgroup. Their epidemiological analysis, therefore, contributes to the investigation of both the overall effect of mixtures, and to disentangling the role of specific compounds, which cannot be achieved based on GIS data and questionnaire data only.
Water contaminants
A serious concern arises from the observation of excesses of bladder cancer and birth defects in populations exposed to chlorination by-products in drinking water. Such studies, however, derived exposure estimates mainly from questionnaires and routine information. A large biomarker study aiming at developing and validating biomarkers of exposure to chlorination by-products would quantify the impact of these compounds and would potentially provide new mechanistic insights into their action on the exposed population.
Pesticides, endocrine disruptors
The main limitation of past biomarker-based investigations is that most pesticides are not genotoxic, so that we do not have the amount of information that characterizes studies with DNA and protein adducts from other exposures. In general, relatively little is known on the role of nongenotoxic exposures in carcinogenesis. The new opportunities offered by epigenomics and other omics, and their application on existing biosamples, are particularly valuable for nongenotoxic agents.
It is now clear that international efforts to validate biomarkers are needed before these are used in practice. An example is the Environmental Cancer Risk, Nutrition and Individual Susceptibility (ECNIS) network, which aims at creating and perusing a 'molecular epidemiology' database (see www.episat.org). Among other initiatives, pooled analyses have been conducted, for example, on bulky DNA adducts as a reliable predictor for lung cancer in cohort studies [2] . Full validation encompasses not only the usual technical validation, that is, robustness of the marker and its ability to represent an underlying biological phenomenon, but also the ability to predict disease in a longitudinal framework. New biomarkers such as those produced through proteomics, transcriptomics, and metabonomics can considerably contribute to our understanding of the disease process [3 ] , but they need to be studied in the context of longitudinal studies, and typically biobanks.
Biomarkers and improved exposure assessment using existing biobanks
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Key points
Omics technology offers a great potential for deriving biomarkers. Novel analytical approaches are aiming to identify intermediate biomarkers.
Including biomarkers analyses in longitudinal frameworks seems to offer a promising potential to refine the modeling of carcinogenesis. suffers from the disadvantage of often requiring large amounts of biological material (e.g., serum, DNA), which exceed those that can be made available by most biobanks (omics platforms may be an exception to the need for large volumes, see [4] calibrated estimates of fiber intake using a 24-h recall instrument to adjust measures based on a FFQ: they observed that less accurate instrument (FFQ) tends to flatten dose-response curves, as people with low intakes tend to overestimate and conversely people with high intakes tend to underreport their intakes. The purpose of calibration is to adjust the dose-response curve estimated over the whole population so that it fits the more reliable measures derived from the subsample. In general, measurement error leads to an attenuation of dose-response curves and calibration corrects for misclassification by applying a correction factor (or de-attenuation factor) over the whole cohort. The same concept is illustrated in Fig. 1 , suggesting an integration between longitudinal prospective studies and case-control or cross-sectional studies.
On this basis, we propose a three-step approach for conducting exposure assessment within longitudinal studies: use of GIS (or questionnaire)-based exposure assessment over the whole cohort; exposure biomarker measurements in subsets of the general population of the same areas or in subsets of the cohorts; and de-attenuation. The underlying principle is to use a more accurate tool for exposure ascertainment than would be possible in the whole cohort (step 2) and to use these refined results to adjust the measurement available for the full cohort.
The best way to calibrate measurements comes probably from the use of biomarkers. As an example of calibration in environmental epidemiology, consider the Avonmouth study, in which a population exposed to high levels of cadmium has been studied. The exposure classification for participant identification has been carried out using an air dispersion model. Distance from the source was used as a proxy. Subsequently, urine samples and questionnaire data on occupation and lifestyle have been collected from a subset of the population (n ¼ 250) to assess cadmium dose (urinary cadmium) and markers of early renal damage (N-acetyl-b-D-glucosaminidase, retinol binding protein, and alpha-1-microglobulin). Then biomarker data were used to assess exposure level in the whole population [5] .
Calibration clearly requires careful considerations regarding the study design, the sample size, and the subpopulation sampling scheme. Uniform sampling of the subpopulation on which the more reliable exposure assessment will be performed is the simplest option. However, in case of a heterogeneous distribution of the exposure within the overall population, this approach has statistical limitations. A stratified sampling procedure, oversampling the most exposed subpopulations can be implemented. For example, if we want to address cadmium exposure by measuring urinary cadmium levels, it is likely that only very few people are heavily exposed, based on the concept of 'proximity as a proxy'. Uniform sampling will give rise to large confidence intervals of the measures, whereas stratified sampling by levels of exposure will provide more precise estimates.
Biomarkers and longitudinal settings: toward dynamic models for chronic diseases
Discovering new biomarkers for disease risk raises important design issues. In a case-control study design, markers of clinically overt disease can be identified, but preclinical markers or markers associated with exposure would require prediagnostic biological samples. In prospective cohort studies, samples are collected years before the disease onset, yet the nature of the biomarkers that could be derived from their analysis mainly depends on the (usually nonobserved) time to clinical onset. Specifically, if biomarker identification relies on biological samples collected long before onset, the resulting biomarkers are likely to be related to the impact of exposure, whereas biomarkers derived from samples collected closer to the disease onset will reflect early damage or the disease itself.
The 'meet-in-the-middle' approach has recently been introduced [1] and precisely accounts for the role of these two types of biomarkers in the pathological pathway. It also aims at identifying the possible common biomarkers of exposure and of disease/early damage, therefore, defining putative intermediate biomarkers. The rationale of this strategy is under development at Imperial College, based on metabolomic profiles and is illustrated in Fig. 2 . In practice, the relationship between metabonomic spectral data and disease status is first analyzed. In parallel, associations between spectral variables and exposure are assessed, thus defining putative biomarkers of disease end point and exposure, respectively. We define intermediate biomarkers, as spectral regions that reflect molecular entity(-ies) both mediating the metabonomic effect of exposure and impacting the disease risk. These can be identified by the intersecting regions from the lists of putative markers of exposure and of disease outcome.
As illustrated above, the inclusion of the time to onset component is essential to provide new insight into molecular mechanisms involved in carcinogenesis. One natural way to do this would imply a stratification of individuals according to the time lag between blood sampling and disease onset. The 'omic'-wide analytical methods could then be applied on the full population and each stratum separately, and it can be seen (e.g. through a meta-analytical approach) whether there is a difference in the outcome for the whole vs. the stratified population. A key point would be to define the strata according to time to onset. This could be arbitrarily set or more realistically estimated from the data. Specifically, measurement error and/or biological variation might be incorporated via a latent class approach in which lag time would act as a covariate on the latent class. This would empirically define the partitioning of the population and no arbitrary choice over the time windows would have to be made.
Although classical statistical models to analyzing omics data serve the purpose of identifying signals and separating them from noise, little has been done in chronic diseases to model time into the exposure-biomarkerdisease continuum. Recently, Galea et al. [6 ] have proposed to generalize mathematical approaches initially designed to study infectious disease to chronic diseases epidemiology. In that setting, biomarkers should not be assessed synchronically, as usually done, but diachronically and even ideally their full evolution along time should be considered. In addition, the concept of 'epidemic curve' should be mimicked, that is, the onset of diseases should 'causally' follow exposure according to a meaningful time pattern reflecting the 'induction-latency' process [e.g., diethylstilbestrol
Biomarkers in molecular epidemiology studies Vineis and Chadeau-Hyam 103 (23 cases) and on the incomplete understanding of the underlying biological processes, that study aimed at estimating the number of individuals incubating the disease. The population was divided into the four following compartments (Fig. 3) : S (susceptible), individuals who were not exposed to the vCJD agent; I (infected), individuals asymptomatically replicating the agent; R (removed from the infected population), individuals with clinical symptoms; D, deaths from vCJD; and M, other cause mortality. In the absence of a reliable diagnostic test, state I cannot be observed (it is hidden), but only the union of states S and I can be observed. By analogy, in cancer epidemiology, the hidden state I would correspond to individuals with a growing but undetected tumor, and state R would group people with a diagnosed tumor. The S-I transition happens when the patient's first cell enters the carcinogenesis process and the corresponding probability mainly depends on exposure. The I-R transition occurs when the tumor is diagnosed. The p(I-R) transition probability depends on the dynamic of the tumor growth and controls the time spent in the asymptomatic stage of the disease, from which the time to onset can be derived. To ensure the time spent in state I (incubation period) is modeled as flexibly as possible, state I can be subdivided into k substages, where k is either fixed or estimated. Finally, transition out of state R corresponds to death from cancer (R-D transition) or from other cause mortality (R-M transition). Modeling these transitions involves survival and competing risk processes. The Bayesian estimation of the model, relying on a so-called Quasi-Observed Markov Chain (QOMiC) approach, would, therefore, provide an estimation of the distribution of cancer occurrence probability and more importantly of the length of the asymptomatic stage of the disease. This kind of approach requires longitudinal estimates of individual exposure to be plugged in. Such estimates can be derived directly if several samples, collected at different time points, are available for each patient. Otherwise, generalizing the calibration process presented above, these can be deconvolved by combining one single biomarker measurement and questionnaire data (e.g., cotinine dosage and smoking related questionnaire data to quantify smoking exposure).
Conclusion
Though the use of biomarkers (particularly omics) in longitudinal epidemiological studies can be very rewarding, it is clear that the field is still in its infancy. The challenges we face are unknown reliability and accuracy of marker measurements; lack of repeat samples in presence of potentially large intraindividual variability; large amounts of biological samples needed; only vague knowledge of time relationships between exposure, intermediate biomarkers (endophenotype) and disease onset; incomplete understanding of mechanisms of carcinogenesis; and incomplete mathematical modeling. However, from such challenges, extremely interesting results may emerge. 
